By Fineline Cube 
Johnson & Johnson (J&J, NYSE: JNJ) reported fourth‑quarter revenue of $24.6 billion, up 9.1% year‑on‑year (YOY), bringing full‑year 2025 revenue to $94.2 billion, an increase of 6.0% compared to 2024. The company highlighted key regulatory approvals, pipeline milestones, and strategic acquisitions as primary growth catalysts.
Full‑Year 2025 Performance & Strategic Highlights
| Metric | Q4 2025 | Full‑Year 2025 | YOY Growth |
|---|---|---|---|
| Total Revenue | $24.6 B | $94.2 B | +6.0% |
| Innovative Medicine | — | $60.4 B | +5.3% |
| MedTech | — | $33.8 B | +5.4% |
| 2026 Revenue Guidance | — | $100.5 B (guidance) | +6.7% vs. 2025 |
Key 2025 Achievements:
- Caplyta approved for major depressive disorder
- Rybrevant faspro + Lazcluze approved for non‑small cell lung cancer
- Tecvayli + Darzalex faspro milestone data may establish new standard of care for relapsed/refractory multiple myeloma
- Halda Therapeutics acquisition completed
- OTTAVA surgical robotics system registration application submitted
Innovative Medicine Segment – Growth Drivers
| Product | 2025 Sales | YOY Growth | Key Indication |
|---|---|---|---|
| Daratumumab | $14.35 B | +22% | Multiple myeloma |
| Guselkumab | $5.155 B | +39.8% | Immunology (psoriasis) |
| Apalutamide | $3.574 B | +17.2% | Prostate cancer |
| Golimumab | $2.668 B | +21.7% | Rheumatoid arthritis |
| Ciltacabtagene autoleucel | $1.887 B | +94.3% | CAR‑T cell therapy |
| Esketamine | $1.696 B | +57% | Treatment‑resistant depression |
| Amivantamab/lazertinib | $734 M | — | NSCLC |
Segment Performance: Innovative Medicine revenue reached $60.4 billion, up 5.3% YOY, with oncology and immunology franchises delivering double‑digit growth offsetting mature product decline.
MedTech Segment & 2026 Outlook
- MedTech Revenue: $33.8 billion, up 5.4% YOY, driven by the Shockwave acquisition and net M&A contributing +1.1% to growth
- Growth Drivers: Cardiovascular portfolio expansion (Shockwave), continued robotics adoption, and international market penetration
- 2026 Guidance: Management reaffirmed full‑year revenue guidance of $100.5 billion, reflecting confidence in oncology momentum and MedTech integration
Forward‑Looking Statements
This brief contains forward‑looking statements regarding J&J’s 2026 revenue guidance, pipeline development, and commercial expectations for key products. Actual results may differ due to competitive pressures, regulatory changes, and macroeconomic factors.-Fineline Info & Tech